NovoCure (NVCR) Accounts Payables (2014 - 2026)

NovoCure has disclosed Accounts Payables across 13 years of filings, most recently posting $127.2 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $127.2 million, up 33.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $127.2 million (up 33.81% YoY), and the FY2025 annual result was $122.2 million, up 16.32% from the prior year.
• Accounts Payables came in at $127.2 million for Q1 2026 at NovoCure, up from $122.2 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $127.2 million in Q1 2026 to a low of $69.2 million in Q1 2022.
• The 5-year median for Accounts Payables is $90.2 million (2024), against an average of $93.4 million.
• Across the five-year window, Accounts Payables surged 40.72% in 2022 and grew 3.29% in 2023, its largest moves.
• NovoCure's Accounts Payables stood at $85.2 million in 2022, then climbed by 10.79% to $94.4 million in 2023, then advanced by 11.33% to $105.1 million in 2024, then increased by 16.32% to $122.2 million in 2025, then gained by 4.1% to $127.2 million in 2026.
• The last three Accounts Payables figures came in at $127.2 million (Q1 2026), $122.2 million (Q4 2025), and $118.9 million (Q3 2025), per Business Quant data.